Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker

Hideki Mori, Hidekazu Suzuki, Hideki Mori, Hidekazu Suzuki

Abstract

Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.

Keywords: Gastroesophageal reflux; Helicobacter pylori; Peptic ulcer; Potassium; Proton pump inhibitors.

Conflict of interest statement

Conflicts of interest: Hidekazu Suzuki received scholarship funds for the research from Daiichi-Sankyo, EA Pharma, Otsuka Pharmaceutical, and Tsumura, and received service honoraria from Astellas, AstraZeneca, Daiichi-Sankyo, Otsuka Pharmaceutical, Mylan EPD, Takeda Pharmaceutical, and Tsumura.

Figures

Figure 1
Figure 1
Strategy of gastroesophageal reflux disease (GERD) treatment. (A) Conventional strategy of GERD treatment (an abridged edition of the Evidence-based Clinical Practice Guidelines for GERD 2015 published by the Japanese Society of Gastroenterology). Initial treatment is administration of proton pump inhibitor (PPI) standard dose for 8 weeks. Then, maintenance treatment is administration of PPI half dose daily. If incomplete healing occurs, maintenance with continuous PPI standard dose is permissible. On-demand PPI treatment is alternative management strategy. (B) The authors propose a new strategy of GERD treatment considering the effectiveness of potassium-competitive acid blocker (P-CAB). Initial treatment is 4-week treatment with P-CAB standard dose for severe erosive esophagitis. Four-week treatment with P-CAB or 8-week treatment with PPI are recommended as an initial therapy for mild erosive esophagitis or non-erosive reflux disease (NERD). Then, maintenance treatment is administration of P-CAB half dose daily. If incomplete healing, maintenance with continuous P-CAB standard dose is permissible. Continuous PPI standard or half dose daily is one of the options. On-demand P-CAB treatment is a workable alternative management strategy. The severity of reflux esophagitis is classified according to the Los Angeles classification. EE, erosive esophagitis.
Figure 2
Figure 2
Strategy of proton pump inhibitor (PPI)-resistant gastroesophageal reflux disease (GERD) treatment. (A) Conventional strategy of PPI-resistant GERD treatment (an abridged edition of the Evidence-based Clinical Practice Guidelines for GERD 2015 published by the Japanese Society of Gastroenterology). First choice is double dose PPI therapy. Switching to the other PPI is an option. Addition of prokinetics to PPI is effective in some cases. (B) The authors propose a new strategy of PPI-resistant GERD treatment. First choice is administration of potassium-competitive acid blocker (P-CAB) standard dose. Addition of prokinetics to P-CAB may have an additional effect.
Figure 3
Figure 3
Strategy of proton pump inhibitor (PPI)-resistant Helicobacter pylori (H. pylori) eradication treatment. (A) Conventional strategy of H. pylori eradication treatment (an abridged edition of Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report published by the European Helicobacter and Microbiota Study Group). In areas of low clarithromycin (CAM) resistance (< 15%), amoxicillin (AMX), CAM, and PPI triple therapy is the recommended first-line treatment. In areas of high CAM resistance (> 15%) and low metronidazole (MTZ) resistance (< 15%), AMX, MTZ, and PPI triple therapy is recommended. In areas of dual resistance, bismuth quadruple therapy is recommended. Quinolone containing therapy and bismuth quadruple therapy are recommended as rescue therapy. (B) The authors propose a new strategy of H. pylori eradication treatment. AMX, CAM, and potassium-competitive acid blocker (P-CAB) triple therapy is sufficient treatment even for CAM resistant strains. AMX, MTZ, P-CAB, or PPI triple therapy, quinolone containing therapy and bismuth quadruple therapy may be recommended as rescue therapy.

References

    1. Mori H, Suzuki H, Matsuzaki J, et al. Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for Helicobacter pylori strains containing the gyrA mutation. Helicobacter. 2016;21:286–294. doi: 10.1111/hel.12286.
    1. Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United European Gastroenterol J. 2016;4:380–387. doi: 10.1177/2050640615618043.
    1. Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154:302–318. doi: 10.1053/j.gastro.2017.07.049.
    1. Tajima A, Koizumi K, Suzuki K, et al. Proton pump inhibitors and recurrent bleeding in peptic ulcer disease. J Gastroenterol Hepatol. 2008;23(suppl 2):S237–S241. doi: 10.1111/j.1440-1746.2008.05557.x.
    1. Mo C, Sun G, Wang YZ, Lu ML, Yang YS. PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: systematic review and meta-analysis. PLoS One. 2015;10:e0131558. doi: 10.1371/journal.pone.0131558.
    1. Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11 doi: 10.1177/1756283X17745776. 1756283X17745776.
    1. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15:355–370. doi: 10.1053/bega.2001.0184.
    1. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25–35. doi: 10.5056/jnm.2013.19.1.25.
    1. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(suppl 3):27–36. doi: 10.1046/j.1365-2036.1999.00022.x.
    1. Deshpande N, VS, VVRK, et al. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene. 2016;9:159–164. doi: 10.1016/j.mgene.2016.06.004.
    1. Andersson T, Holmberg J, Röhss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol. 1998;45:369–375. doi: 10.1046/j.1365-2125.1998.t01-1-00702.x.
    1. Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28:966–972.
    1. Kuo CH, Lu CY, Shih HY, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20:16029–16036. doi: 10.3748/wjg.v20.i43.16029.
    1. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol. 2002;58:453–458. doi: 10.1007/s00228-002-0502-1.
    1. Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295–314. doi: 10.1586/ecp.09.8.
    1. Sachs G, Shin JM, Munson K, et al. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:1383–1401. doi: 10.1046/j.1365-2036.2000.00837.x.
    1. Yu KS, Bae KS, Shon JH, et al. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol. 2004;44:73–82. doi: 10.1177/0091270003261321.
    1. Kim YG, Jang BI, Kim TN. A matched case-control study of a novel acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection. Gut and liver. 2010;4:25–30. doi: 10.5009/gnl.2010.4.1.25.
    1. Takahashi N, Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther. 2018;364:275–286. doi: 10.1124/jpet.117.244202.
    1. Yi S, Lee H, Jang SB, et al. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers. Aliment Pharmacol Ther. 2017;46:337–346. doi: 10.1111/apt.14148.
    1. Kim E, Kim A, Yi S, et al. Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects. Eur J Clin Pharmacol. 2018;74:1261–1272. doi: 10.1007/s00228-018-2502-9.
    1. Sunwoo J, Oh J, Moon SJ, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018;48:206–218. doi: 10.1111/apt.14818.
    1. Li CY, Su M, Yan YY, et al. KFP-H008 blocks gastric acid secretion through inhibiting H+-K+-ATPase. Eur J Pharmacol. 2017;810:112–119. doi: 10.1016/j.ejphar.2017.06.020.
    1. Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;30:334–344. doi: 10.5056/jnm18029.
    1. Klatte DCF, Gasparini A, Xu H, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153:702–710. doi: 10.1053/j.gastro.2017.05.046.
    1. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719–730. doi: 10.1111/apt.13325.
    1. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther. 2015;42:1315–1326. doi: 10.1111/apt.13414.
    1. Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048–1059. doi: 10.1111/apt.13588.
    1. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751–767. doi: 10.1007/s00535-016-1227-8.
    1. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–1810. doi: 10.1053/gast.1997.v112.pm9178669.
    1. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23:998–1017. doi: 10.1016/S0149-2918(01)80087-4.
    1. Kawano S, Murata H, Tsuji S, et al. Randomized comparative study of omeprazole and famotidine in reflux esophagitis. J Gastroenterol Hepatol. 2002;17:955–959. doi: 10.1046/j.1440-1746.2002.02785.x.
    1. Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol. 2009;15:990–995. doi: 10.3748/wjg.15.990.
    1. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007:CD003244.
    1. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240–251. doi: 10.1111/apt.13461.
    1. Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rop. 2017;6:175–180. doi: 10.3892/br.2016.828.
    1. Kinoshita Y, Hongo M. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol. 2012;107:522–530. doi: 10.1038/ajg.2012.19.
    1. Adachi K, Komazawa Y, Mihara T, et al. Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis. J Clin Gastroenterol. 2004;38:297–298. doi: 10.1097/00004836-200403000-00020.
    1. Lim HC, Kim JH, Youn YH, Lee EH, Lee BK, Park H. Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: a prospective randomized, double-blind study. J Neurogastroenterol Motil. 2013;19:495–502. doi: 10.5056/jnm.2013.19.4.495.
    1. Takeuchi T, Takahashi Y, Kawaguchi S, et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol. 2018;33:623–630. doi: 10.1111/jgh.13970.
    1. Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux ssophagitis. Digestion. 2017;95:156–161. doi: 10.1159/000456072.
    1. Iwakiri K, Sakurai Y, Shiino M, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol. 2017;10:439–451. doi: 10.1177/1756283X17705329.
    1. Shinozaki S, Osawa H, Hayashi Y, et al. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 2017;7:231–235. doi: 10.3892/br.2017.947.
    1. Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24:1550–1561. doi: 10.3748/wjg.v24.i14.1550.
    1. Leodolter A, Penagini R. On-demand therapy is a valid strategy in GERD patients: pros and cons. Dig Dis. 2007;25:175–178. doi: 10.1159/000103880.
    1. Umezawa M, Kawami N, Hoshino S, et al. Efficacy of on-demand therapy using 20-mg vonoprazan for mild reflux esophagitis. Digestion. 2018;97:309–315. doi: 10.1159/000485795.
    1. Kato M, Ito N, Demura M, Kubo K, Mabe K, Harada N. Study for every other day administration of vonoprazan in maintenance treatment of erosive GERD: study protocol for a multicentre randomised cross-over study. BMJ Open Gastroenterol. 2018;5:e000197. doi: 10.1136/bmjgast-2017-000197.
    1. Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther. 2012;36:972–979. doi: 10.1111/apt.12059.
    1. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868–877.
    1. Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008;13:532–541. doi: 10.1111/j.1523-5378.2008.00643.x.
    1. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20:153–167. doi: 10.2133/dmpk.20.153.
    1. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36:414–425. doi: 10.1111/j.1365-2036.2012.05211.x.
    1. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439–1446. doi: 10.1136/gutjnl-2015-311304.
    1. Nishizawa T, Suzuki H, Fujimoto A, et al. Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. J Clin Biochem Nutr. 2017;60:208–210. doi: 10.3164/jcbn.16-86.
    1. Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23:e12495. doi: 10.1111/hel.12495.
    1. Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017;22 doi: 10.1111/hel.12374.
    1. Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354–361. doi: 10.1007/s00535-017-1407-1.
    1. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30. doi: 10.1136/gutjnl-2016-312288.
    1. Dahal K, Sharma SP, Kaur J, Anderson BJ, Singh G. Efficacy and safety of proton pump inhibitors in the long-term aspirin users: a meta-analysis of randomized controlled trials. Am J Ther. 2017;24:e559–e569. doi: 10.1097/MJT.0000000000000637.
    1. Iwakiri R, Higuchi K, Kato M, et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2014;40:780–795. doi: 10.1111/apt.12907.
    1. Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017;33:973–980. doi: 10.1080/03007995.2017.1281110.
    1. Sugano K, Kinoshita Y, Miwa H, Takeuchi T. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. Aliment Pharmacol Ther. 2012;36:115–125. doi: 10.1111/j.1365-2036.2012.05133.x.
    1. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67:1033–1041. doi: 10.1136/gutjnl-2017-314852.
    1. Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67:1042–1051. doi: 10.1136/gutjnl-2017-314010.
    1. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323–2330. doi: 10.3748/wjg.v16.i19.2323.
    1. Otsuka T, Sugimoto M, Inoue R, et al. Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. Gut. 2017;66:1723–1725. doi: 10.1136/gutjnl-2016-313312.
    1. Hongo M, Fujimoto K. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45:618–624. doi: 10.1007/s00535-010-0207-7.
    1. Jianu CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther. 2012;36:644–649. doi: 10.1111/apt.12012.
    1. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crow-ell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10:e0128004. doi: 10.1371/journal.pone.0128004.
    1. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448–457. doi: 10.1007/s11894-010-0141-0.
    1. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther. 2006;24:613–619. doi: 10.1111/j.1365-2036.2006.03015.x.
    1. Tai SY, Chien CY, Wu DC, et al. Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. PLoS One. 2017;12:e0171006. doi: 10.1371/journal.pone.0171006.
    1. Keeling DJ, Laing SM, Senn-Bilfinger J. SCH 28080 is a lumenally acting, K+-site inhibitor of the gastric (H+ + K+)-ATPase. Biochem Pharmacol. 1988;37:2231–2236. doi: 10.1016/0006-2952(88)90586-2.
    1. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103:20–26. doi: 10.1111/j.1572-0241.2007.01544.x.
    1. Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55:409–418. doi: 10.1007/s40262-015-0326-7.
    1. Kojima Y, Takeuchi T, Sanomura M, et al. Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? a multicenter prospective cross-sectional study. Digestion. 2018;97:70–75. doi: 10.1159/000484217.
    1. Miyamoto S, Matsuno Y, Kato M, et al. Parietal cell protrusions and dilated oxyntic glands from use of vonoprazan. Am J Gastroenterol. 2017;112:1899–1901. doi: 10.1038/ajg.2017.364.
    1. Takimoto M, Tomita T, Yamasaki T, et al. Effect of vonoprazan, a potassium-competitive acid blocker, on the 13C-urea breath test in Helicobacter pylori-positive patients. Dig Dis Sci. 2017;62:739–745. doi: 10.1007/s10620-016-4439-0.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi